x

Join Advarra

Learn more about our company team, careers, and values. Join Advarra’s Talented team to take on engaging work in a dynamic environment.

See Jobs

Daniel Eisenman, PhD, RBP, SM(NRCM), CBSP

Executive Director, Biosafety Services, Advarra

Prior to joining Advarra, Daniel Eisenman served as Biosafety Officer at UNC Chapel Hill and the Medical University of South Carolina. Eisenman holds a PhD in Molecular Biology and Immunology from Augusta University, as well as various professional certifications in biological safety, including the Registered Biological Safety Professional (RBP) and Certified Biological Safety Professional (CBSP) certifications through the American Biological Safety Association (ABSA) and as a Specialist Microbiologist in Biological Safety (SM(NRCM)) through the American Society for Microbiology (ASM) National Registry of Certified Microbiologists (NRCM). He is also a devoted longtime educator, having taught microbiology at the undergraduate and graduate levels. Eisenman currently serves on the ABSA Owned Course Committee and is a regular speaker at clinical research conferences.

Dan Eisenman

Latest Posts by Daniel

 
Blog

Operation Warp Speed for Rare Diseases: Expected Boom in Drug Development and Approval

As FDA CBER prepares to launch Operation Warp Speed for Rare Diseases, there is an expected rapid growth in gene therapy.

Read Now
6 min. read
Read more
 
Blog

How Centralized IBC Review Can Benefit Gene Therapy Research

Understand the risks and regulatory requirements for gene therapy research and how a biosafety review can benefit this type of research.

Read Now
4 min. read
Read more
 
Blog

Reporting Unexpected Incidents to the IBC

Find out which unexpected events you should report to the IBC during a clinical trial, and what to expect from the IBC's review.

Read Now
3 min. read
Read more
 
Blog

IBC vs. IRB: What’s the Difference?

Gene therapy research is full of promise, but because of the risks, it’s a highly regulated space requiring oversight by an institutional biosafety committee (IBC).

Read Now
4 min. read
Read more
 
Abstract

FDA Guidance on Shedding and Environmental Impact in Clinical Trials Involving Gene Therapy Products

Our IBC experts authored “FDA Guidance on Shedding and Environmental Impact in Clinical Trials Involving Gene Therapy Products” in Applied Biosafety.

Read Now
Read more
 
Webinar

A Guide for Successful Cell and Gene Therapy Research

Understand the unique regulatory, clinical, and manufacturing requirements for cell and gene therapy research.

Watch Now
Read more
 
Blog

Safe Sharps Handling When Dispensing Investigational Products

Care must be taken to avoid sharps-related injuries and exposures when preparing investigational products for clinic transportation.

Read Now
4 min. read
Read more
 
Blog

Clean Bench vs Biosafety Cabinet: What’s the Difference?

Using hoods with biological materials depends on directional airflow, and specialized airflow is necessary when handling hazardous materials.

Read Now
4 min. read
Read more
 
Blog

mRNA Clinical Trials: Key Regulatory Considerations

Responses to the most frequently asked questions regarding mRNA technology and clinical trial regulatory requirements.

Read Now
5 min. read
Read more
 
Blog

Does This Study Require IBC Review?

While clinical research professionals are familiar with the role of the IRB to protect research subjects, most are unfamiliar with the added need for an Institutional Biosafety Committee (IBC).

Read Now
4 min. read
Read more
 
Abstract

A Changing World in Gene Therapy Research: Exciting Opportunities for Medical Advancement and Biosafety Challenges

October 4, 2021

Our IBC experts authored the article “A Changing World in Gene Therapy Research: Exciting Opportunities for Medical Advancement and Biosafety...

Read Now
Read more
 
Podcast

Daniel Eisenman, Paul Gulig, and Adam Soloff Explore The Exponential Rise of Gene Therapy and Unlocking Its Potential Promise

In this podcast, Daniel Eisenmann talks with Adam Soloff and Paul Gulig for a discussion on the growth and the promise of gene therapy.  

Listen Now
Read more